Healthcare Equipment and Supplies
Company Overview of Ortho-Clinical Diagnostics, Inc.
Ortho-Clinical Diagnostics, Inc. provides solutions for screening, diagnosing, monitoring, and confirming diseases for the transfusion medicine community and laboratories worldwide. It offers integrated clinical chemistry and immunoassay testing systems, chemistry systems, immunodiagnostic systems, and automation solutions that streamline and standardize laboratory workflow. The company also provides donor screening solutions, such as Ortho Summit System, a system for screening assays, automation, and information management; T-cruzi ELISA test systems; and screening assays and information management screening assays for blood donor and plasma centers. In addition, it offers immunohematology ...
100 Indigo Creek Drive
Rochester, NY 14626
Founded in 1974
Key Executives for Ortho-Clinical Diagnostics, Inc.
Chairman and Chief Executive Officer
Executive Vice President for Commercial
Compensation as of Fiscal Year 2014.
Ortho-Clinical Diagnostics, Inc. Key Developments
Ortho-Clinical Diagnostics, Inc. Announces Management Appointments
Jul 8 14
Ortho-Clinical Diagnostics, Inc. (OCD) unveiled its newly expanded executive leadership team following the acquisition of the company by The Carlyle Group from Johnson & Johnson. The company announced the appointments of: Alex Socarras as Executive Vice President, Commercial, Robert Yates as Chief Operating Officer, Jeffrey D. Capello as Chief Financial Officer and Michael Schlesinger as General Counsel. Prior to joining Ortho Clinical Diagnostics, Mr. Socarras was a senior vice president and CEO of healthcare in South West Europe at Siemens Healthcare. He also served as their vice president and region CEO of Latin America. Robert Yates joins Ortho Clinical Diagnostics from EMD Millipore, where he served as president and CEO, leading the company through a period of outstanding growth. Jeffrey D. Capello was most recently Executive Vice President and Chief Financial Officer at Boston Scientific and has more than 29 years of experience in various roles in which he drove operational improvement and implemented strategies to drive value. Mr. Schlesinger has extensive experience in corporate practice and M&A, and provided in-house counsel for a variety of venture-backed firms. As a former partner and corporate lawyer at Latham & Watkins, LLP.
Robert Yates to Join Ortho-Clinical Diagnostics, Inc. as Chief Operating Officer
Jun 16 14
The Carlyle Group announced that Robert Yates will become Chief Operating Officer of Ortho-Clinical Diagnostics, Inc. subject to the close of Carlyle's acquisition of OCD from Johnson & Johnson, which is expected in mid-2014. In this newly-created role, Mr. Yates will report directly to incoming OCD Chairman and CEO Dr. Martin Madaus. Mr. Yates will also be appointed to OCD's board of directors. Mr. Yates will join OCD from Merck KGaA where he was President and CEO of EMD/Merck Millipore.
Ortho-Clinical Diagnostics to Appoint Martin D. Madaus as Chairman and Chief Executive Officer
Feb 27 14
The Carlyle Group announced that Dr. Martin D. Madaus will become Chairman and Chief Executive Officer of Ortho-Clinical Diagnostics (OCD) subject to the close of Carlyle's acquisition of OCD from Johnson & Johnson, which is expected in mid-2014. Dr. Madaus is the current Executive Chairman of Quanterix's Board of Directors. He most recently served as President, Chairman and Chief Executive Officer of Millipore Corp. Dr. Madaus was President, Chief Executive Officer and Head of North American Operations for Roche Diagnostics Corp. He also held a number of senior-level sales, marketing and product management positions with Boehringer Mannheim Corp. in both Germany and the United States. In addition to Quanterix, Dr. Madaus is a director at Carlyle portfolio company PPD, Mettler Toledo, and Covidien.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 16, 2014